CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Cogent Biosciences, Inc. - COGT CFD

    9.75
    0.1%
    0.09
    Low: 9.51
    High: 9.75
    Market Trading Hours* (UTC) Opens on Friday at 13:30

    Mon - Fri: 13:30 - 20:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.09
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Cogent Biosciences Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 9.76
    Open* 9.66
    1-Year Change* -32.78%
    Day's Range* 9.51 - 9.75
    52 wk Range 9.65-17.54
    Average Volume (10 days) 556.01K
    Average Volume (3 months) 14.14M
    Market Cap 1.03B
    P/E Ratio -100.00K
    Shares Outstanding 85.47M
    Revenue N/A
    EPS -2.20
    Dividend (Yield %) N/A
    Beta 1.68
    Next Earnings Date Nov 13, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 27, 2023 9.76 0.09 0.93% 9.67 9.79 9.44
    Sep 26, 2023 9.64 -0.03 -0.31% 9.67 10.16 9.62
    Sep 25, 2023 9.94 0.12 1.22% 9.82 10.04 9.54
    Sep 22, 2023 9.97 -0.16 -1.58% 10.13 10.21 9.94
    Sep 21, 2023 10.22 0.46 4.71% 9.76 10.26 9.64
    Sep 20, 2023 9.94 -0.67 -6.31% 10.61 10.61 9.83
    Sep 19, 2023 10.65 0.01 0.09% 10.64 10.77 10.40
    Sep 18, 2023 10.68 -0.89 -7.69% 11.57 11.78 10.51
    Sep 15, 2023 11.70 0.09 0.78% 11.61 11.79 11.47
    Sep 14, 2023 11.67 0.20 1.74% 11.47 11.90 11.47
    Sep 13, 2023 11.47 -0.61 -5.05% 12.08 12.25 11.46
    Sep 12, 2023 12.13 0.21 1.76% 11.92 12.46 11.92
    Sep 11, 2023 12.19 0.00 0.00% 12.19 12.31 12.01
    Sep 8, 2023 12.22 0.25 2.09% 11.97 12.23 11.80
    Sep 7, 2023 12.02 -0.51 -4.07% 12.53 12.59 11.95
    Sep 6, 2023 12.59 -0.10 -0.79% 12.69 12.83 12.39
    Sep 5, 2023 12.76 -0.02 -0.16% 12.78 13.19 12.68
    Sep 1, 2023 12.94 0.95 7.92% 11.99 13.05 11.95
    Aug 31, 2023 12.18 -0.01 -0.08% 12.19 12.37 12.11
    Aug 30, 2023 12.20 0.13 1.08% 12.07 12.21 11.99

    Cogent Biosciences, Inc. Events

    Time (UTC) Country Event
    Monday, November 13, 2023

    Time (UTC)

    12:00

    Country

    US

    Event

    Q3 2023 Cogent Biosciences Inc Earnings Release
    Q3 2023 Cogent Biosciences Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 7.871 22.499 9.734
    Revenue 0 7.871 22.499 9.734
    Total Operating Expense 148.239 75.551 90.07 54.677 45.739
    Selling/General/Admin. Expenses, Total 26.212 19.638 17.422 10.968 7.454
    Research & Development 121.627 55.913 72.648 43.709 38.285
    Operating Income -148.239 -75.551 -82.199 -32.178 -36.005
    Interest Income (Expense), Net Non-Operating 3.989 0.467 0.144 0.267 1.153
    Other, Net 4.009 2.811 -0.246 0.078 0.32
    Net Income Before Taxes -140.241 -72.273 -74.808 -31.833 -34.532
    Net Income After Taxes -140.241 -72.273 -74.808 -31.833 -34.532
    Net Income Before Extra. Items -140.241 -72.273 -74.808 -31.833 -34.532
    Net Income -140.241 -72.273 -74.808 -31.833 -34.532
    Total Adjustments to Net Income 0 -104.4 0 -0.016
    Income Available to Common Excl. Extra. Items -140.241 -72.273 -179.208 -31.833 -34.548
    Income Available to Common Incl. Extra. Items -140.241 -72.273 -179.208 -31.833 -34.548
    Diluted Net Income -140.241 -72.273 -179.208 -31.833 -34.548
    Diluted Weighted Average Shares 58.7397 38.7308 11.0813 7.62008 6.22392
    Diluted EPS Excluding Extraordinary Items -2.3875 -1.86603 -16.1722 -4.17751 -5.55084
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -2.38069 -1.86603 -16.4693 -4.17751 -5.55084
    Gain (Loss) on Sale of Assets 0 7.493
    Unusual Expense (Income) 0.4
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Revenue
    Total Operating Expense 47.085 43.237 43.745 37.221 35.855
    Selling/General/Admin. Expenses, Total 8.214 7.199 7.003 6.885 6.376
    Research & Development 38.871 36.038 36.742 29.936 29.479
    Operating Income -47.085 -43.237 -43.745 -37.221 -35.855
    Interest Income (Expense), Net Non-Operating 2.741 2.268 2.11 1.5 0.272
    Other, Net 0.268 2.382 2.017 0.659 0.656
    Net Income Before Taxes -44.076 -38.587 -39.618 -35.062 -34.927
    Net Income After Taxes -44.076 -38.587 -39.618 -35.062 -34.927
    Net Income Before Extra. Items -44.076 -38.587 -39.618 -35.062 -34.927
    Net Income -44.076 -38.587 -39.618 -35.062 -34.927
    Income Available to Common Excl. Extra. Items -44.076 -38.587 -39.618 -35.062 -34.927
    Income Available to Common Incl. Extra. Items -44.076 -38.587 -39.618 -35.062 -34.927
    Diluted Net Income -44.076 -38.587 -39.618 -35.062 -34.927
    Diluted Weighted Average Shares 74.7533 70.7349 70.6187 69.5764 49.3889
    Diluted EPS Excluding Extraordinary Items -0.58962 -0.54552 -0.56101 -0.50394 -0.70718
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.58962 -0.54552 -0.56101 -0.49819 -0.70718
    Gain (Loss) on Sale of Assets
    Total Adjustments to Net Income
    Unusual Expense (Income) 0 0.4
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 264.966 222.633 244.912 40.591 81.002
    Cash and Short Term Investments 259.276 219.684 242.19 37.424 78.594
    Cash & Equivalents 139.886 219.684 242.19 37.424 55.671
    Short Term Investments 119.39 0 22.923
    Total Receivables, Net 0 2 1.668
    Accounts Receivable - Trade, Net 0 2 1.668
    Prepaid Expenses 4.435 2.949 2.722 1.167 0.74
    Other Current Assets, Total 1.255 0
    Total Assets 300.81 232.092 250.916 49.423 85.927
    Property/Plant/Equipment, Total - Net 31.099 4.477 4.749 7.15 3.251
    Property/Plant/Equipment, Total - Gross 32.5 5.036 5.161 11.781 6.747
    Accumulated Depreciation, Total -1.401 -0.559 -0.412 -4.631 -3.496
    Other Long Term Assets, Total 4.745 4.982 1.255 1.682 1.674
    Total Current Liabilities 26.849 17.077 13.094 13.248 24.945
    Accounts Payable 5.842 3.483 0.732 3.183 1.519
    Accrued Expenses 18.903 10.299 5.847 7.856 3.798
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 2.104 3.295 6.515 2.209 19.628
    Total Liabilities 45.075 17.908 16.249 17.661 25.693
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 18.226 0.831 3.155 4.413 0.748
    Total Equity 255.735 214.184 234.667 31.762 60.234
    Preferred Stock - Non Redeemable, Net
    Common Stock 0.07 0.044 0.032 0.03 0.03
    Additional Paid-In Capital 601.153 399.713 322.454 155.624 152.275
    Retained Earnings (Accumulated Deficit) -411.214 -270.973 -198.7 -123.892 -92.059
    Other Equity, Total -0.104 0 -0.012
    Total Liabilities & Shareholders’ Equity 300.81 232.092 250.916 49.423 85.927
    Total Common Shares Outstanding 69.8934 43.8059 32.3479 7.66576 7.51449
    Redeemable Preferred Stock 65.83 85.4 110.881 0 0
    Total Preferred Shares Outstanding 0.08105 0.10329 0.13224
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 226.27 264.966 296.417 330.675 194.733
    Cash and Short Term Investments 220.264 259.276 289.094 325.562 191.047
    Cash & Equivalents 160.698 139.886 140.568 325.562 191.047
    Prepaid Expenses 4.751 4.435 6.068 3.858 3.686
    Total Assets 263.198 300.81 331.56 366.052 206.869
    Property/Plant/Equipment, Total - Net 32.153 31.099 30.375 30.482 5.275
    Other Long Term Assets, Total 4.775 4.745 4.768 4.895 6.861
    Total Current Liabilities 21.12 26.849 23.551 27.658 17.879
    Accounts Payable 4.172 5.842 4.093 3.492 4.015
    Accrued Expenses 15.933 18.903 15.201 19.545 10.552
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 1.015 2.104 4.257 4.621 3.312
    Total Liabilities 39.635 45.075 41.618 46.667 19.006
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 18.515 18.226 18.067 19.009 1.127
    Total Equity 223.563 255.735 289.942 319.385 187.863
    Redeemable Preferred Stock 62.31 65.83 65.83 71.4 78.4
    Common Stock 0.071 0.07 0.07 0.066 0.046
    Additional Paid-In Capital 610.967 601.153 595.801 584.453 411.024
    Retained Earnings (Accumulated Deficit) -449.801 -411.214 -371.596 -336.534 -301.607
    Total Liabilities & Shareholders’ Equity 263.198 300.81 331.56 366.052 206.869
    Total Common Shares Outstanding 70.9468 69.8934 69.858 65.7077 45.8193
    Total Preferred Shares Outstanding 0.07705 0.08105 0.08105 0.08738 0.09533
    Other Current Assets, Total 1.255 1.255 1.255 1.255
    Short Term Investments 59.566 119.39 148.526
    Other Equity, Total 0.016 -0.104 -0.163
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -140.241 -72.273 -74.808 -31.833 -34.532
    Cash From Operating Activities -118.638 -58.763 -35.85 -41.514 -32.489
    Cash From Operating Activities 0.842 0.147 0.72 1.293 1.321
    Non-Cash Items 20.01 11.343 43.554 3.11 2.875
    Changes in Working Capital 0.751 2.02 -5.316 -14.084 -2.153
    Cash From Investing Activities -124.718 -1.719 8.42 23.159 -10.531
    Capital Expenditures -6.863 -1.719 0 -0.033 -0.549
    Other Investing Cash Flow Items, Total -117.855 0 8.42 23.192 -9.982
    Cash From Financing Activities 163.558 37.976 232.196 0.108 70.346
    Financing Cash Flow Items 0 -0.085 -2.056
    Issuance (Retirement) of Stock, Net 163.558 38.061 232.196 0.108 72.402
    Net Change in Cash -79.798 -22.506 204.766 -18.247 27.326
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -38.587 -140.241 -100.623 -65.561 -30.634
    Cash From Operating Activities -39.517 -118.638 -89.23 -54.79 -28.334
    Cash From Operating Activities 0.529 0.842 0.422 0.166 0.069
    Non-Cash Items 3.301 20.01 16.998 9.773 4.666
    Changes in Working Capital -4.76 0.751 -6.027 0.832 -2.435
    Cash From Financing Activities 0.445 163.558 163.243 162.253 0.138
    Financing Cash Flow Items 0 0 0
    Issuance (Retirement) of Stock, Net 0.445 163.558 163.243 162.253 0.138
    Net Change in Cash 20.812 -79.798 -79.116 105.878 -28.637
    Cash From Investing Activities 59.884 -124.718 -153.129 -1.585 -0.441
    Capital Expenditures -1.103 -6.863 -4.896 -1.585 -0.441
    Other Investing Cash Flow Items, Total 60.987 -117.855 -148.233

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Cogent Biosciences, Inc. Company profile

    About Cogent Biosciences Inc

    Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. The Company's most advanced program is CGT9486, a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation, as well as other mutations in KIT exon 17, to treat Systemic Mastocytosis (SM) and gastrointestinal stromal tumors (GIST). GT9486 has demonstrated clinical activity and safety results in a Phase I/II clinical trial in patients with GIST, supporting accelerated timelines to proof-of-concept in SM.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Cogent Biosciences Inc revenues decreased from $7.9M to $0K. Net loss applicable to common stockholders decreased 60% to $72.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Acquired in-process research and develop decrease from $46.9M (expense) to $0K, Other income increase from $779K to $2.5M (income).

    Industry: Bio Therapeutic Drugs

    275 Wyman Street
    3rd Floor
    WALTHAM
    MASSACHUSETTS 02451
    US

    Income Statement

    • Annual
    • Quarterly

    News

    How to Trade The Triple Top

    Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

    14:13, 27 September 2023
    USA flag on the background of stock charts. Financial system in USA

    Q4 lookahead: US indices starting to show signs of trouble?

    US indices start to draw attention as traders focus on the outlook for Q4.

    07:20, 27 September 2023

    USD/JPY Climbs Towards Key Highs

    USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

    11:32, 26 September 2023

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    People also watch

    BTC/USD

    27,052.75 Price
    +3.030% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    US100

    14,709.00 Price
    +0.610% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    XRP/USD

    0.52 Price
    +1.940% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    ETH/USD

    1,657.41 Price
    +3.870% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading